Literature DB >> 3014469

Live varicella vaccine in healthy individuals.

M Just, R Berger, D Luescher.   

Abstract

Eight hundred healthy seronegative children and 32 adults were vaccinated with the Oka-strain live attenuated varicella vaccine (Varilrix), manufactured by Smith Kline-RIT, Belgium. The vaccine was safe (no side effects) in healthy individuals, highly immunogenic (dose-dependent induction of humoral antibodies and specific cell-mediated immune response), and highly protective against clinical varicella. The simultaneous administration of a measles-mumps-rubella vaccine together with the varicella vaccine is possible, although combination in the same syringe was less effective than simultaneous administration in different arms. Various observations suggest that the risk of contracting zoster in adulthood may well be reduced for varicella vaccinees. Based on our results, it is recommended that seronegative hospital staff be vaccinated. Furthermore, if the varicella vaccine should prove to be cost effective, large-scale immunization of healthy children may be indicated.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3014469

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  5 in total

1.  The epidemiology of varicella-zoster virus infections: the influence of varicella on the prevalence of herpes zoster.

Authors:  G P Garnett; B T Grenfell
Journal:  Epidemiol Infect       Date:  1992-06       Impact factor: 2.451

Review 2.  Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adults.

Authors:  Kristine Macartney; Anita Heywood; Peter McIntyre
Journal:  Cochrane Database Syst Rev       Date:  2014-06-23

3.  The epidemiology of varicella-zoster virus infections: a mathematical model.

Authors:  G P Garnett; B T Grenfell
Journal:  Epidemiol Infect       Date:  1992-06       Impact factor: 2.451

4.  Safety, reactogenicity, and immunogenicity of live attenuated varicella vaccine in children between 1 and 9 years of age with atopic dermatitis.

Authors:  Hans Wolfgang Kreth; Peter Hans Hoeger
Journal:  Eur J Pediatr       Date:  2006-07-12       Impact factor: 3.860

5.  Controversies in chicken-pox immunization.

Authors:  Swati Y Bhave
Journal:  Indian J Pediatr       Date:  2003-06       Impact factor: 5.319

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.